These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38618727)

  • 1. Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach.
    Qadir MI; Ahmed B; Hussain N
    Crit Rev Immunol; 2024; 44(5):41-50. PubMed ID: 38618727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
    Rapoport AP; Meisenberg B; Sarkodee-Adoo C; Fassas A; Frankel SR; Mookerjee B; Takebe N; Fenton R; Heyman M; Badros A; Kennedy A; Jacobs M; Hudes R; Ruehle K; Smith R; Kight L; Chambers S; MacFadden M; Cottler-Fox M; Chen T; Phillips G; Tricot G
    Bone Marrow Transplant; 2002 Feb; 29(4):303-12. PubMed ID: 11896427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
    Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
    Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin's disease.
    Turturro F; Arnold MD; Frist AY; Seth P
    Leuk Lymphoma; 2002 Jun; 43(6):1323-8. PubMed ID: 12153002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo.
    Trieu Y; Wen XY; Skinnider BF; Bray MR; Li Z; Claudio JO; Masih-Khan E; Zhu YX; Trudel S; McCart JA; Mak TW; Stewart AK
    Cancer Res; 2004 May; 64(9):3271-5. PubMed ID: 15126369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
    Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
    J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease.
    Wellmann A; Otsuki T; Vogelbruch M; Clark HM; Jaffe ES; Raffeld M
    Blood; 1995 Sep; 86(6):2321-8. PubMed ID: 7662979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Hodgkin's disease.
    Rooney CM; Bollard C; Huls MH; Gahn B; Gottschalk S; Wagner HJ; Anderson R; Prentice HG; Brenner MK; Heslop HE
    Ann Hematol; 2002; 81 Suppl 2():S39-42. PubMed ID: 12611071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
    Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
    Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Majolino I; Pearce R; Taghipour G; Goldstone AH
    J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma.
    Laurence AD; Goldstone AH
    Semin Hematol; 1999 Jul; 36(3):303-12. PubMed ID: 10462330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatment and immunotherapy of Hodgkin's lymphoma.
    Klimm B; Schnell R; Diehl V; Engert A
    Haematologica; 2005 Dec; 90(12):1680-92. PubMed ID: 16330443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
    Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PA
    Cancer J; 2005; 11(5):425-31. PubMed ID: 16259874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
    Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B
    Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells.
    Rooney CM; Roskrow MA; Suzuki N; Ng CY; Brenner MK; Heslop H
    Ann Oncol; 1998; 9 Suppl 5():S129-32. PubMed ID: 9926252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis.
    Sarris AH; Luthra R; Papadimitracopoulou V; Waasdorp M; Dimopoulos MA; McBride JA; Cabanillas F; Duvic M; Deisseroth A; Morris SW; Pugh WC
    Blood; 1996 Sep; 88(5):1771-9. PubMed ID: 8781434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.